News Releases

November 3, 2023
MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the highest planned doses Patient recruitment of the study’s dose-escalation portion is complete, with final
Displaying 1 - 10 of 34
* These releases may contain price sensitive information